Development and validation of a clinical nAb assay for a replicating oncolytic virus
QPS, LLLC and Boehringer Ingelheim Pharmaceuticals, Inc. collaborated to develop a robust cell-based method to detect and titer nAb responses in patient sera to support clinical development of an oncolytic rhabdovirus and cancer vaccine platform based on the VSV-GP virus. This Poster is one of the winners of the 20th WRIB Poster Award.